期刊文献+

E1B缺陷腺病毒dl1520联合化疗药物DDP体外对鼻咽癌细胞杀伤及诱导凋亡作用 被引量:2

The effect of E1B-deleted adenovirus, dl1520 with DDP on NPC cell killing and apoptosis in vitro
下载PDF
导出
摘要 目的探讨E1B-55KDa缺陷腺病毒dl1520与DDP联合体外对鼻咽癌细胞的杀伤及诱导凋亡作用。方法采用MTT法体外测定细胞生长抑制率,流式细胞仪检测细胞凋亡。结果MOI(感染复数)=0.032、0.16、0.8、4、20、100时dl1520对CNE-2细胞的生长抑制率分别为2.78%、7.41%、10.19%、24.07%、45.37%、67.59%,而dl1520+DDP的抑制率分别为29.63%、32.41%、40.74%、52.78%、66.67%、74.07%,P<0.01;1.5μg/mlDDP24h诱导CNE-2细胞凋亡的比例为1.7%,dl1520在MOI=0.1、1、10、100时诱导的凋亡比例分别为1.2%、1.3%、14.1%、2.7%,而当dl1520与DDP联合后诱导的凋亡比例分别为1.8%、3%、18%、3.2%。结论dl1520与DDP联合可显著增强DDP对CNE-2细胞的杀伤及诱导细胞凋亡作用。 Objective To evaluate the anti-NPC effect of E1B-55Kda deleted adenovirus dl1520 with DDP in vitro. Methods Detecting the cytotoxicity by MTT assay; apoptosis cells detected by flow cytometry. Results In MTT assay, the inhibitory rate of cell viability in dl1520 group were 2.78%, 7.41%, 10.19%, 24.07%, 45.37%, 67.59% when MOI(multiplicity of infection)were 0, 0.032, 0.16, 0.8, 4, 20, 100 respectively; But in dl1520+DDP group,the inhibitory rate was 24.07%, 29.63%, 32.41%, 40.74%, 52.78%, 66.67%, 74.07% respectively, P<0.01. When MOI were 0, 0.1, 1, 10, 100,the percent age of apoptosis cells was 1.2%, 1.2%, 1.3%, 14.1%, 2.7% respectively. After plus DDP,the percent age of apoptosis cells was 1.7%, 1.8%, 3%, 18%, 3.2% respectively . Conclusion dl1520 with DDP may significantly potentiate the cell-killing and apoptosis on NPC cell.
出处 《郧阳医学院学报》 2004年第6期321-323,F002,共4页 Journal of Yunyang Medical College
基金 国家杰出青年基金(编号39825124)
关键词 dl1520 DDP 鼻咽癌 癌细胞 细胞毒作用 细胞凋亡 dl1520 DDP NPC cell cytotoxicity apoptosis
  • 相关文献

参考文献9

  • 1[1]Pennisi E. Training viruses to attack cancers[J]. Science, 1998,282(5392):1 244-1 246.
  • 2[2]Barker DD,Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection[J]. Virology, 1987,156(1):107-121.
  • 3[3]Sanchez-Prieto R, Quintanilla M, Cano A, et al. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene[J]. Oncogene, 1996,13(5):1 083-1 092.
  • 4[4]Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein[J]. Nature,1992,357(6373):82-83.
  • 5[5]Kao CC, Yew PR, Berk AJ. Domains required for in vitro association between the cellular p53 and the Ad2 E1B55K proteins[J]. Virology, 1990,179(2):806-814.
  • 6[6]Bischoff JR, Kim DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells[J]. Science, 1996,274(5286):373-376.
  • 7[7]Boulanger PA, Blair GE. Express and interactions of human adenovirus oncoproteins[J]. Biochem J, 1991,275(2):281-299.
  • 8[8]Vousden KH. Regulation of the cell cycle by oncoproteins[J]. Semin Cancer Biol, 1995,6(2):109-116.
  • 9[9]Martin ME, Berk AJ. Adenovirus E1B55K represses p53 activation in vitro[J]. J Virol, 1998,72(4):3 146-3 154.

同被引文献10

  • 1彭吉林,罗慧玲,刘然义,曾益新.E1B缺陷腺病毒dl1520预感染CNE-2细胞对其致瘤性的影响[J].郧阳医学院学报,2005,24(2):72-73. 被引量:1
  • 2Pennisi E. Training viruses to attack cancers[J]. Science, 1998,282(5392):1 244-1 246.
  • 3Nemunaitis J, Ganly I, Khuri F, et al . Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55KD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase Ⅱ trial[J]. Cancer Research, 2000,60(20):6 359-6 366.
  • 4Mulvihill S, Warren R, Venook A, et al . Safety and feasibility of injection with an E1B-55Kda gene-deleted, replication-selective adenovirus(ONYX-015) into primary carcinomas of the pancreas: a phaseⅠtrial[J]. Gene Therapy, 2001,8(4):308-315.
  • 5Heise C, Lemmon M, Kirn D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration[J]. Clinical Cancer Research, 2000,6(12):4 908-4 914.
  • 6Heise CC, Williams A, Olesch J, et al . Efficacy of a replication-competent adenovirus(ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects[J]. Cancer Gene Therapy, 1999,6(6):499-504.
  • 7Pennisi E.Training viruses to attack cancers[J]. Science, 1998,282(5392):1 244-1 246.
  • 8McCormick F. Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015[J]. Semin Cancer Biol,2000,10(6):453-459.
  • 9Ries SJ, Brandts CH, Chung AS, et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520(ONYX-015)[J]. Nat Med,2000,6(10):1128-1133.
  • 10Matsubara S,Wada Y,Gardner TA,et al. A conditional replication-competent adenoviral vector,Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis[J]. Cancer Res, 2001,61(16):6 012-6 019.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部